Do analysts prefer MIRA or INTS?

Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 949.83%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better earnings & valuation, MIRA or INTS?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is MIRA or INTS more profitable?

Intensity Therapeutics' return on equity of -136.82% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Intensity Therapeutics N/A -136.82% -105.82%

Which has higher earnings and valuation, KALA or INTS?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is KALA or INTS more profitable?

Intensity Therapeutics' return on equity of -136.82% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Intensity Therapeutics N/A -136.82% -105.82%

Which has stronger valuation and earnings, RKTO or INTS?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is RKTO or INTS more profitable?

Intensity Therapeutics' return on equity of -136.82% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Intensity Therapeutics N/A -136.82% -105.82%

Intensity Therapeutics (INTS) Competitors

$3.57 -0.21 (-5.50%)

As of 01:57 PM Eastern

Compare

INTS vs. MIRA, ELUT, KALA, RKTO, and RNXT

Should you buy Intensity Therapeutics stock or one of its competitors? MarketBeat compares Intensity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intensity Therapeutics include MIRA Pharmaceuticals (MIRA), Elutia (ELUT), KALA BIO (KALA), Rocket One Inc. Common Stock (RKTO), and RenovoRx (RNXT). These companies are all part of the "med - biomed/gene" industry.

How does Intensity Therapeutics compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for Intensity Therapeutics. MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Intensity Therapeutics	Neutral

Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 949.83%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

MIRA Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market.

Intensity Therapeutics' return on equity of -136.82% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Summary

Intensity Therapeutics beats MIRA Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to Elutia?

Intensity Therapeutics (NASDAQ:INTS) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Intensity Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Intensity Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 949.83%. Elutia has a consensus price target of $6.00, indicating a potential upside of 510.38%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Intensity Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 7.1% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 27.6% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Intensity Therapeutics' average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
Elutia	Neutral

Elutia has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Elutia	$12.29M	3.42	$53.38M	$0.86	1.14

Elutia has a net margin of 312.09% compared to Intensity Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats Intensity Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, KALA BIO's average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
KALA BIO	Neutral
Intensity Therapeutics	Neutral

Intensity Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Intensity Therapeutics' return on equity of -136.82% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Intensity Therapeutics	N/A	-136.82%	-105.82%

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 7.1% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market.

KALA BIO presently has a consensus price target of $1,018.75, suggesting a potential upside of 44,699.91%. Intensity Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 949.83%. Given KALA BIO's higher probable upside, equities research analysts clearly believe KALA BIO is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Intensity Therapeutics beats KALA BIO on 8 of the 12 factors compared between the two stocks.

How does Intensity Therapeutics compare to Rocket One Inc. Common Stock?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Rocket One Inc. Common Stock presently has a consensus target price of $5.00, suggesting a potential upside of 287.60%. Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 949.83%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Intensity Therapeutics' return on equity of -136.82% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Rocket One Inc. Common Stock has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the broader market.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 1 mentions for Rocket One Inc. Common Stock and 0 mentions for Intensity Therapeutics. Rocket One Inc. Common Stock's average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Neutral
Intensity Therapeutics	Neutral

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Comparatively, 7.1% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Intensity Therapeutics beats Rocket One Inc. Common Stock on 10 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to RenovoRx?

Intensity Therapeutics (NASDAQ:INTS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Intensity Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

In the previous week, RenovoRx had 9 more articles in the media than Intensity Therapeutics. MarketBeat recorded 9 mentions for RenovoRx and 0 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 beat RenovoRx's score of -0.60 indicating that Intensity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
RenovoRx	Negative

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 7.1% of Intensity Therapeutics shares are held by company insiders. Comparatively, 9.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Intensity Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 949.83%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 882.66%. Given Intensity Therapeutics' higher possible upside, equities analysts clearly believe Intensity Therapeutics is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

RenovoRx has higher revenue and earnings than Intensity Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
RenovoRx	$1.49M	26.20	-$11.17M	-$0.33	N/A

Intensity Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats Intensity Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.87M	$3.29B	$6.44B	$11.66B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-0.64	18.96	23.83	23.35
Price / Sales	N/A	300.06	529.24	114.09
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.72	7.99	10.46	6.62
Net Income	-$11.61M	$23.89M	$3.56B	$337.25M
7 Day Performance	-16.54%	-4.56%	-1.94%	-3.41%
1 Month Performance	-29.82%	0.47%	0.29%	0.36%
1 Year Performance	-70.60%	34.47%	19.72%	22.27%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	2.9789 of 5 stars	$3.57 -5.5%	$37.50 +949.8%	-68.6%	$9.87M	N/A	N/A	2,021
MIRA MIRA Pharmaceuticals	0.6443 of 5 stars	$1.01 -2.9%	N/A	-28.6%	$42.44M	N/A	N/A	2
ELUT Elutia	2.8332 of 5 stars	$0.99 -4.8%	$6.00 +506.0%	-47.9%	$42.36M	$12.29M	1.15	180	Gap Up
KALA KALA BIO	2.342 of 5 stars	$2.24 -6.3%	$1,018.75 +45,379.9%	-98.9%	$41.64M	N/A	N/A	30	Gap Up
RKTO Rocket One Inc. Common Stock	1.8102 of 5 stars	$2.14 -3.6%	$5.00 +133.6%	+6.9%	$40.94M	N/A	N/A	4	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. MIRA, ELUT, KALA, RKTO, and RNXT

How does Intensity Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Intensity Therapeutics compare to Elutia?

Summary

How does Intensity Therapeutics compare to KALA BIO?

Summary

How does Intensity Therapeutics compare to Rocket One Inc. Common Stock?

Summary

How does Intensity Therapeutics compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. MIRA, ELUT, KALA, RKTO, and RNXT

How does Intensity Therapeutics compare to MIRA Pharmaceuticals?

Which has better earnings & valuation, MIRA or INTS?

Do institutionals and insiders hold more shares of MIRA or INTS?

Does the media favor MIRA or INTS?

Do analysts prefer MIRA or INTS?

Which has more volatility and risk, MIRA or INTS?

Is MIRA or INTS more profitable?

Summary

How does Intensity Therapeutics compare to Elutia?

Which has more risk and volatility, INTS or ELUT?

Do analysts rate INTS or ELUT?

Do institutionals and insiders believe in INTS or ELUT?

Does the media refer more to INTS or ELUT?

Which has preferable earnings and valuation, INTS or ELUT?

Is INTS or ELUT more profitable?

Summary

How does Intensity Therapeutics compare to KALA BIO?

Does the media prefer KALA or INTS?

Which has higher earnings and valuation, KALA or INTS?

Is KALA or INTS more profitable?

Do institutionals and insiders have more ownership in KALA or INTS?

Which has more risk and volatility, KALA or INTS?

Do analysts recommend KALA or INTS?

Summary

How does Intensity Therapeutics compare to Rocket One Inc. Common Stock?

Do analysts rate RKTO or INTS?

Which has stronger valuation and earnings, RKTO or INTS?

Is RKTO or INTS more profitable?

Which has more risk & volatility, RKTO or INTS?

Does the media prefer RKTO or INTS?

Do institutionals & insiders have more ownership in RKTO or INTS?

Summary

How does Intensity Therapeutics compare to RenovoRx?

Which has more risk and volatility, INTS or RNXT?

Does the media favor INTS or RNXT?

Do insiders & institutionals have more ownership in INTS or RNXT?

Do analysts rate INTS or RNXT?

Which has higher valuation and earnings, INTS or RNXT?

Is INTS or RNXT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools